Literature DB >> 6732217

Evaluation of Sch 29,482 in the eradication of Neisseria meningitidis from nasopharyngeal carriers.

M P Pugsley, D L Dworzack, C C Sanders, W E Sanders.   

Abstract

Fifty-eight chronic carriers of Neisseria meningitidis were given 250 mg of Sch 29,482 or placebo orally every 6 h for 4 days. Although 22 of 29 subjects taking Sch 29,482 became culture negative while taking the drug, only five were culture negative 2 weeks posttherapy. There were no significant adverse reactions.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6732217      PMCID： PMC185560          DOI： 10.1128/AAC.25.4.494

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Attempted prophylaxis against meningococcal infection using intramuscular penicillin.

Authors:  M S Artenstein; T H Lamson; J R Evans
Journal:  Mil Med       Date:  1967-12       Impact factor: 1.437

2.  Prediction of antimeningococcic chemoprophylactic efficacy.

Authors:  P D Hoeprich
Journal:  J Infect Dis       Date:  1971-02       Impact factor: 5.226

3.  Antibiotic prophylaxis of carriers of sulfadiazine-resistant meningococci.

Authors:  J M Dowd; D Blink; C H Miller; P F Frank; W E Pierce
Journal:  J Infect Dis       Date:  1966-10       Impact factor: 5.226

4.  Comparison of the in-vitro activity of Sch 29482 with thirteen other beta-lactam antibiotics against Neisseria meningitidis and Neisseria gonorrhoeae (including penicillinase-producing isolates).

Authors:  J R Dillon; M Pauzé; H Yeung; G S Bezanson
Journal:  J Antimicrob Chemother       Date:  1982-02       Impact factor: 5.790

5.  Oral absorption and tolerance in man, of a new penem antibiotic, Sch 29428.

Authors:  R Gural; C Lin; M Chung; E Oden; C Digiore
Journal:  J Antimicrob Chemother       Date:  1982-02       Impact factor: 5.790

6.  Effectiveness of rifampin in eradicating the meningococcal carrier state in a relatively closed population: emergence of resistant strains.

Authors:  C E Weidmer; T B Dunkel; F S Pettyjohn; C D Smith; A Leibovitz
Journal:  J Infect Dis       Date:  1971-08       Impact factor: 5.226

7.  Rifampin. Levels in serum and saliva and effect on the meningococcal carrier state.

Authors:  L F Devine; D P Johnson; C R Hagerman; W E Pierce; S L Rhode; R O Peckinpaugh
Journal:  JAMA       Date:  1970-11-09       Impact factor: 56.272

8.  Effect of rifampin and minocycline on meningococcal carrier rates.

Authors:  R B Guttler; G W Counts; C K Avent; H N Beaty
Journal:  J Infect Dis       Date:  1971-08       Impact factor: 5.226

9.  Side effects of minocycline: a double-blind study.

Authors:  W L Fanning; D W Gump; R A Sofferman
Journal:  Antimicrob Agents Chemother       Date:  1977-04       Impact factor: 5.191
  9 in total
  2 in total

Review 1.  Prophylactic use of antibiotics for prevention of meningococcal infections: systematic review and meta-analysis of randomised trials.

Authors:  A Fraser; A Gafter-Gvili; M Paul; L Leibovici
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-03       Impact factor: 3.267

Review 2.  Antibiotics for preventing meningococcal infections.

Authors:  Anca Zalmanovici Trestioreanu; Abigail Fraser; Anat Gafter-Gvili; Mical Paul; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2013-10-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.